Clinical trials: PD-1 Inhibitors
Advanced Cancer, Advanced Solid Tumor
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05525455
- Testing
- TT-816, A PD-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Teon Therapeutics, Inc.
Nonsmall Cell Lung Cancer, NSCLC
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following…
- Trial name
- NCT02973789
- Testing
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Where
- 124 sites in United States, Austria and 16 more
- Volunteers
- 291 people
- Sponsor
- NovoCure GmbH
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer
- Trial name
- NCT05057247
- Testing
- Duvelisib, Docetaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kartik Sehgal, MD
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
This is an open label phase 2 study to evaluate the combination of Vigil™ and nivolumab in advanced or metastatic NSCLC that is progressive on or after one prior platinum-based systemic therapy.
- Conditions
- Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02639234
- Testing
- Vigil™, Nivolumab
- Where
- 3 sites in United States
- Sponsor
- Gradalis, Inc.
Advanced Solid Tumor
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
- Trial name
- NCT05429398
- Testing
- Linperlisib Tablet
- Volunteers
- 118 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Limited-stage Small-cell Lung Cancer
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy…
- Trial name
- NeoSCLC-001 (NCT06375109)
- Testing
- Tislelizumab, Carboplatin injection, Cisplatin injection
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital, Capital Medical University
Colorectal Cancer, Rectal Cancer
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal…
- Trial name
- NCT07227636
- Testing
- Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 284 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Immunotherapy
IMMUNO-FIT Observational Study
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers.
- Conditions
- Neoplasms, Immunotherapy, Physical Fitness, Quality of Life
- Trial name
- NCT07354971
- Testing
- Observational Study - No Study Intervention
- Where
- United Kingdom
- Volunteers
- 67 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors
This clinical study focused on patients with digestive system tumors resistant to PD-1 inhibitors, and explored the reversal resistance of epigenetic drugs (decitabine) and TKI drugs (anlotinib) in this part of patients.
- Trial name
- NCT04611711
- Testing
- decitabine＋ TQB2450 injection, decitabine＋ TQB2450 injection＋Anlotinib
- Volunteers
- 60 people
- Sponsor
- Peking University
Non-small Cell Lung Cancer (NSCLC)
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can…
- Trial name
- NCT05553834
- Testing
- Alirocumab and Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Rectal Neoplasms
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer
Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed.
- Trial name
- NECI (NCT05420584)
- Testing
- Arterial chemoembolization, Tislelizumab Injection, XELOX
- Where
- China
- Volunteers
- 83 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Colorectal Cancer
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy.
- Trial name
- NCT05414461
- Testing
- Combinations
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
ESCC, Tislelizumab
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis.
- Conditions
- ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
- Trial name
- NCT07531979
- Testing
- Tislelizumab, Becotatug Vedotin, Cisplatin
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Metastatic Cancer
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
The aim of this study is to assess the effectiveness of a battery of autoantibodies to predict the occurrence of immune-related adverse events (irAEs) in patients with cancer who will be treated with immune checkpoint inhibitors…
- Conditions
- Cancer, Metastatic Cancer, Solid Organ Cancer
- Trial name
- AUTENTIC (NCT03868046)
- Testing
- Treatment with immune checkpoint inhibitors., Blood tests.
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Hospital Universitario Araba
Advanced NSCLC
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after…
- Trial name
- NCT06751901
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Malignant Pleural Mesothelioma, Advanced
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced…
- Trial name
- NCT06031636
- Testing
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital